New method for identifying herv-derived epitopes
AssigneesErvimmune, Centre Leon Berard, Universite Claude Bernard Lyon 1, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsStéphane DEPIL, Vincent ALCAZER
Life of this patent
Estimating the term…
Abstract
Methods for identifying HERV-derived T cell epitopes associated with cancer, and peptides that are or that include epitopes identified by the methods, expression vectors encoding the peptides, cytotoxic T lymphocytes (CTLs) of a subject treated with the peptides or vectors and engineered T cells expressing T-cell receptors recognizing the peptides. Also, the peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular the use of the peptides, expression vectors, CTLs or engineered T cells for use in preventing or treating cancer in a subject in need thereof.
Claims20
1-15. (canceled)
A method for identifying Human endogenous retroviruses (HERVs)-derived T cells epitopes associated with at least one cancer, wherein said method comprises the following steps:
- (a) identifying HERVs associated with at least one cancer, and
- (b) selecting T cell epitopes among the HERVs identified in the previous step, and
- wherein said method further comprises at least one of the following steps:
- (i) selecting HERVs associated with a cytotoxic T cells response among the cancer-associated HERVs identified in step (a), said step being between the step (a) and the step (b), and/or
- (ii) assessing the expression at the protein or peptide level of the HERVs-derived T cells epitopes identified in step (b) in tumor samples, said step being after the step (b).
A peptide comprising or consisting of an epitope having a sequence selected from the group comprising or consisting of RMLTDLRAV (SEQ ID NO:
- 3), LMAQAITGV (SEQ ID NO:
- 11), VLQDFDQPI (SEQ ID NO:
- 13), MLLAALMIV (SEQ ID NO:
- 15) and YIDDILCAA (SEQ ID NO:
- 16).
Dependencies are inferred from the claim text.